% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Maia:305222,
      author       = {A. Maia and J. Schuhmacher and S. Nadalin and A.
                      Königsrainer and K. Thiel and A. Nelde and R. S. Zinser and
                      C. Schroeder$^*$ and S. Mattern and S. Singer and H.
                      Bösmüller and H.-G. Rammensee$^*$ and M. W. Löffler$^*$
                      and C. Gouttefangeas$^*$},
      title        = {{E}xceptional tumor-free survival of a patient with
                      metastatic intrahepatic cholangiocarcinoma after surgery and
                      personalized peptide vaccination: revisiting a striking
                      case.},
      journal      = {Journal for ImmunoTherapy of Cancer},
      volume       = {13},
      number       = {10},
      issn         = {2051-1426},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2025-02068},
      pages        = {e012107},
      year         = {2025},
      abstract     = {Cholangiocarcinomas are rare but aggressive liver tumors of
                      high lethality with scarce treatment options. Here we report
                      on the follow-up of a patient diagnosed with an intrahepatic
                      cholangiocarcinoma who experienced repeated tumor
                      recurrences including distant metastasis, therefore facing a
                      dismal prognosis. At present, this patient is tumor-free for
                      more than 8 years following repeated surgery and application
                      of two successive personalized vaccines. In-depth functional
                      immune cell analyses revealed a dominant CD4+ T-cell
                      response against the vaccine antigens with infiltration of
                      the tumor site and immune responses prevailing for years
                      following the last vaccine administration. Additionally,
                      spontaneous tumor neoantigen-specific CD4+ and CD8+ T-cell
                      responses have been detected, which might have contributed
                      to the outstanding outcome witnessed in this patient. This
                      case report highlights vaccination strategies targeting
                      non-mutated antigens as well as the increasingly recognized
                      central role of antitumor CD4+ T cells.},
      keywords     = {Humans / Cholangiocarcinoma: therapy / Cholangiocarcinoma:
                      pathology / Cholangiocarcinoma: immunology /
                      Cholangiocarcinoma: surgery / Bile Duct Neoplasms: therapy /
                      Bile Duct Neoplasms: pathology / Bile Duct Neoplasms:
                      immunology / Cancer Vaccines: therapeutic use / Male /
                      Middle Aged / Precision Medicine: methods / Vaccines,
                      Subunit: therapeutic use / Disease-Free Survival / CD4+T
                      cells (Other) / cancer vaccine (Other) / case report (Other)
                      / metastatic cholangiocarcinoma (Other) / Cancer Vaccines
                      (NLM Chemicals) / Vaccines, Subunit (NLM Chemicals)},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41067882},
      doi          = {10.1136/jitc-2025-012107},
      url          = {https://inrepo02.dkfz.de/record/305222},
}